Acadia Pharmaceuticals (ACAD) Cash from Operations (2010 - 2026)

Acadia Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 33981000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 67.2% year-over-year to 33981000.0 in Q1 2026; TTM through Mar 2026 was 123494000.0, a 17.1% decrease from a year earlier, with the FY2025 full-year figure at 109836000.0, down 30.36% from the prior year.
• Cash from Operations advanced to 33981000.0 in Q1 2026 per ACAD's latest filing, from 48731000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 85389000.0 in Q4 2023 and bottomed at 76329000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 20323000.0 (2025), against an average of 12011941.18.
• Biggest YoY gain for Cash from Operations was 457.97% in 2023; the steepest drop was 8009.35% in 2023.
• Year by year, Cash from Operations stood at 23854000.0 in 2022, then soared by 457.97% to 85389000.0 in 2023, then sank by 52.71% to 40381000.0 in 2024, then tumbled by 220.68% to 48731000.0 in 2025, then soared by 169.73% to 33981000.0 in 2026.
• Per Business Quant, the three latest ACAD Cash from Operations figures stand at 33981000.0 (Q1 2026), 48731000.0 (Q4 2025), and 74288000.0 (Q3 2025).